Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ciba Vision Group

Division of Novartis AG

Latest From Ciba Vision Group

Start-Ups with Vision

The high visibility of new laser technologies for vision correction or refractive surgery, a widely-publicized consumer market, has obscured the fact that there are even greater needs in the ophthalmic market; 13 million patients suffer from age-related macular degeneration, 4-6 million patients suffer from diabetic retinopathy, and 89 million Americans are troubled by "old vision" or presbyopia.
BioPharmaceutical Medical Device

Eyetech Pharmaceuticals Inc.

Eyetech Pharmaceuticals believes that blocking angiogenesis is the best route to improved therapy for age-related macular degeneration and diabetic macular edema, degenerative conditions that frequently and quickly lead to serious vision loss and blindness. The company in-licensed a compound from Gilead Sciences, about to enter pivotal clinical trials, that it thinks does just that.
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Glen Bradley, CEO
    Dr. Adrian Hunter, Optics Central Mktg. & R&D
    John Cheesmond, Group Planning, Fin. & Control
  • Contact Info
  • Ciba Vision Group
    Phone: (770) 476-3937
    11460 John's Creek Pkwy.
    Duluth, GA 30136